1O Safety, pharmacokinetics, efficacy, and biomarker results of SRK-181 (a latent TGFβ1 inhibitor) from a phase I trial (DRAGON trial)

T.A. Yap,J. Gainor,M. McKean,B. Bockorny,M. Barve,R. Sweis,U.N. Vaishampayan, A. Tarhini,D. Kilari, A. Chand, R. Abdul-Karim, D. Park,S. Babu, Y. Ju, S. Dewall, L. Liu, A.M. Kennedy, J. Marantz, L. Gan

ESMO Open（2023）

Cited 0|Views5

No score

Key words

latent tgfβ1 inhibitor,pharmacokinetics

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined